US 11384337
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted A61KA61K2039/5158A61K35/17
Quick answer
US patent 11384337 (Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy) held by Iovance Biotherapeutics, Inc. expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K2039/5158, A61K35/17, A61K39/0011